Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland-Reference-Cited by-同舟云学术

Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland

Published:2023-11 Issue:11 Volume:4 Page:e863-e874
ISSN:2666-5247
Container-title:The Lancet Microbe
language:en
Short-container-title:The Lancet Microbe

Author:

Ramasamy Maheshi N,Kelly Elizabeth J,Seegobin Seth,Dargan Paul I,Payne Ruth,Libri Vincenzo,Adam Matthew,Aley Parvinder K,Martinez-Alier Nuria,Church Alison,Jepson Brett,Khan Mark,Matthews Sam,Townsend G Todd,Vekemans Johan,Bibi Sagida,Swanson Phillip A,Lambe Teresa,Pangalos Menelas N,Villafana Tonya,Pollard Andrew J,Green Justin A,Wildman Eden,Rampling Tommy,Morris Sheila,Shoemaker Kathryn,Aksyuk Anastasia,Padilla Marcelino Giune,Roe Tiffany,Petropoulos Christos J,Wrin Terri,Colton Hayley,Bisnauthsing Karen,Smith Catherine,Leeman Lucy,Galloway James,Nagra Deepak,Lazarus Rajeka,Penciu Florentina,Hunter Ewan,Sahdev Anju,Turner David,Royal Simon,Uriel Alison,Ustianowski Andrew,Moran Ed,Green Christopher,Desai Amisha,Lakeman Nicki,Moore Patrick,Whittington Ashley,Kobielusz Gembala Iwona,Konieczny Marek

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Microbiology (medical),Microbiology

Reference26 articles.

1. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study;Watson;Lancet Infect Dis,2022

2. Antibody evasion by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4 and BA.5;Wang;Nature,2022

3. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant;Andrews;N Engl J Med,2022

4. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study;Costa Clemens;Lancet,2022

5. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study;Jara;Lancet Glob Health,2022

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19 Vaccine development and distribution;International Encyclopedia of Public Health;2025

2. Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study;Vaccines;2024-08-03

3. Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study;The Lancet Microbe;2024-08

4. Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901-Beta SARS-CoV-2 Vaccine in Adults: A Phase I, Prospective, Randomized, Open-Labeled Study;Vaccines;2023-12-01